Business Wire

Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis

Share

Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis.

“DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology to create best in-class topical therapies with superior bioavailability,” said Betsy Hughes-Formella, PhD, Chief Scientific Officer at Dermaliq. “Calcineurin inhibitors for the treatment of psoriasis are a standard of care when given orally, albeit being associated with significant risk for systemic side effects. DLQ02 is designed to overcome the challenges of topical delivery of this drug class with reduced risk profiles. We are convinced DLQ02 has the potential to transform topical psoriasis therapy for millions of patients.”

The randomized, single-center, double-blind, vehicle-controlled Phase 1b/2a trial at the Centre of Human Disease Research (CHDR), Leiden, The Netherlands, is designed to evaluate the safety and efficacy profile of two dose strengths of DLQ02 and its vehicle in patients diagnosed with mild to moderate plaque psoriasis. A targeted total of 36 patients, 12 per treatment group, will be enrolled. Trial completion is expected in Q2 2023.

“DLQ02 is the first of three clinical trials in dermatology we are initiating in 2022, “said Frank Loescher, PhD, CEO & President of Dermaliq. “This is a significant step towards Dermaliq's goal of developing a new generation of superior topical drug therapies and medical skin care products. We can progress rapidly from preclinical to clinical stage building on our comprehensive safety and manufacturing experience with the hyliQTM technology. Based on the same technology (EyeSol® from Novaliq), two ophthalmology products for the treatment of Dry Eye Disease (CyclASol, NOV03), are currently in registration with New Drug Applications (NDAs) submitted to FDA”

About DLQ02

DLQ02 is a liquid topical, calcineurin inhibitor with anti-inflammatory and immunomodulating properties, developed for the treatment of Psoriasis. There remains an unmet need for topical therapies, particularly for localized lesions only affecting limited body surface areas, which are usually not eligible for systemic treatments. DLQ02 has the potential to provide a highly effective and safe treatment option.

About Dermaliq:

Dermaliq Therapeutics, Inc. is a clinical stage pharmaceutical Delaware corporation founded in 2021 through a spin off from Novaliq GmbH to reimagine topical dermatology.

Dermaliq’s mission is to develop a new generation of superior topical drug therapies and medical skin care products with greater efficacy and fewer unwanted side effects for millions of patients. The unique “hyliQTM” technology is driving a growing product pipeline in key dermatological indications. We expect that the hyliQTM technology will offer superior bioavailability, stability and cosmetic acceptability as compared to currently marketed products.

Earlier this year, Dermaliq secured USD 15 million in a series A round to advance the development of three transformative skin care drug therapies including DLQ02. Key shareholders are Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd.

Forward-Looking Disclosures:

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. The information contained in this release is as of August 18, 2022. Dermaliq assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about a potential topical treatment for psoriasis, DLQ02, including its potential benefits and a Phase 1b/2a clinical trial that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. You should not rely on any of these forward-looking statements, including those relating to the potential benefits, safety, and efficacy of DLQ02, hyliQTM, or any of Dermaliq’s other product candidates, the potential benefits or applications of Dermaliq’s hyliQTM technology, Dermaliq’s ability to develop and advance product candidates into and successfully complete clinical trials, including the ongoing and planned clinical trials of DLQ02 and other product candidates, and the timing the commencement of clinical trials, initial and ongoing data availability, and other development milestones.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dermaliq Therapeutics Inc.
Dr. Frank Loescher
Chief Executive Officer
Email: info@dermaliq.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Board International Announces Strategic Alliance With Oliver Wight26.9.2022 12:00:00 CEST | Press release

Board International, the Intelligent Planning Platform which delivers solutions that help organizations plan smarter — enabling actionable insights and better outcomes, today announced a strategic alliance with leading management consultants and business transformation specialists Oliver Wight (AP and EAME). The new partnership will use Board’s Intelligent Planning capabilities in conjunction with Oliver Wight’s Integrated Business Planning (IBP) model, industry-leading business transformation methodology and expertise, to realize customers’ Business Planning vision in a unified, integrated solution. The combined offer from Board and Oliver Wight will empower customers to accelerate change, mitigate risk, and realize rewards faster, whilst ensuring self-sufficient delivery of successful integrated business planning initiatives by aligning people, process, and technology together in one joint offer. “We are excited about the combined impact of this new alliance with Oliver Wight for our

PCTEL Announces its New MultiFin Antenna for Intelligent Transportation Systems Communications26.9.2022 12:00:00 CEST | Press release

PCTEL, Inc. (Nasdaq: PCTI), a leading global provider of wireless technology solutions, today announced its new MultiFin configurable antenna for public safety, fleet management and intelligent transportation applications. The MultiFin 7-in-1 antenna offers a robust RF performance in a discreet, rugged low-profile shark fin design. Configurable and optimized for multiband applications, this antenna allows for easy integration with customers’ existing antenna systems. Mattias Hellgren, PCTEL’s Senior RF Engineer & Product Manager, commented, “Flexibility and adaptability are important to our customers. The new MultiFin antenna allows the simultaneous operation of customers’ existing radio networks (TETRA, TETRAPOL, DMR, P25), along with new LTE 4G and 5G networks and WiFi 6E applications. It is designed to support multi system solutions for diverse applications in public safety, mass transit, telematics, infotainment systems and fleet management. We are excited to offer our new antenna

ALL4PACK Emballage Paris – 21 to 24 November 2022: the leading international trade fair for all sustainable packaging and intralogistics solutions26.9.2022 10:00:00 CEST | Press release

The benchmark event at the end of the year (21-24 November 2022 - Paris Nord Villepinte, France), ALL4PACK Emballage Paris is the leading international trade fair for all sustainable packaging and intralogistics solutions, covering the whole production line, including machines. ALL4PACK is a source of inspiration, offering support to all industry stakeholders who are faced with ongoing and future challenges. Against this backdrop, the fair stands out by decoding market developments and regulations, and by showcasing the latest innovations. A new approach approved by exhibitors ALL4PACK Emballage Paris offers a complete range of packaging and machinery solutions for all types of industry. To date, 1,300 exhibitors are expected, of which about 50% are international exhibiters. In fact, 96% of the exhibition space has already been booked. Various leading companies such as ATLANTA STRETCH, AUER, BFR SYSTEMS, DOMINO, FILPACK, FRANPACK, FROMM, G.MONDINI, GETRA, GOGLIO, ISHIDA, KRONES, MARCHE

Adams Street Hires James Charalambides and Launches European Private Credit Strategy26.9.2022 10:00:00 CEST | Press release

Adams Street Partners, LLC, a private markets investment firm with $50 billion in assets under management, announced the launch of its Private Credit platform in Europe with the appointment of James Charalambides as Partner & Head of the European Private Credit team. Mr. Charalambides will be responsible for leading and managing the firm’s private credit-related efforts in Europe and supporting all aspects of the decision-making process – including sourcing, structuring, reviewing, and negotiating deal opportunities in this space. Mr. Charalambides will report to Bill Sacher, Partner & Head of Private Credit at Adams Street. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005177/en/ Adams Street Partners has announced the launch of its Private Credit platform in Europe with the appointment of James Charalambides as Partner & Head of the European Private Credit team. (Photo: Business Wire) Since launching its inaugural p

Guillaume Jesel Promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development26.9.2022 09:00:00 CEST | Press release

Today, The Estée Lauder Companies (NYSE: EL) (“ELC”) announced that Guillaume Jesel has been promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development, effective immediately. Guillaume will report to Jane Hertzmark Hudis, Executive Group President and also to Tracey T. Travis, Executive Vice President and Chief Financial Officer in her role of overseeing the company’s mergers and acquisitions strategy, for Guillaume’s Luxury Business Development responsibilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005235/en/ Guillaume Jesel has been promoted to President, Global Brands, TOM FORD BEAUTY, BALMAIN BEAUTY and Luxury Business Development (Photo: Business Wire) In this new position, Guillaume will continue to oversee TOM FORD BEAUTY and also be responsible for the overall strategic direction, global development, management and growth of BALMAIN BEAUTY. Guillaume will wo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom